title: Correlation between asparaginase sensitivity and asparagine synthetase protein content, but not mRNA, in acute lymphoblastic leukemia cell lines.
abstract: BACKGROUND
  Asparaginase (ASNase) is an essential component of most treatment protocols for childhood acute lymphoblastic leukemia (ALL). Although increased asparagine synthetase (ASNS) expression may contribute to ASNase resistance, there is conflicting data from patient samples with regard to correlation between ASNS mRNA content and ASNase sensitivity.
  
  
  METHODS
  Both T-cell and B-cell derived ALL cell lines were treated with ASNase and then monitored for cell proliferation, cell death, and ASNS mRNA and protein expression.
  
  
  RESULTS
  Despite elevated ASNS mRNA following ASNase treatment, different ALL cell lines varied widely in translation to ASNS protein. Although ASNS mRNA levels did not consistently reflect ASNase sensitivity, there was an inverse correlation between ASNS protein and ASNase-induced cell death. Expression of ASNS in an ASNase-sensitive cell line resulted in enhanced ASNase resistance, and conversely, siRNA-mediated inhibition of ASNS expression promoted increased drug sensitivity.
  
  
  CONCLUSIONS
  These observations provide an explanation for the ASNase sensitivity of ALL cells and demonstrate the importance of measuring ASNS protein rather than mRNA in predicting ASNase responsiveness.
authors.affiliation: Department of Biochemistry and Molecular Biology, University of Florida Shands Cancer Center, University of Florida College of Medicine, Gainesville, Florida, USA.
authors.forename: Nan
authors.initials: N
authors.lastname: Su
authors.forename: Yuan-Xiang
authors.initials: YX
authors.lastname: Pan
authors.forename: Mi
authors.initials: M
authors.lastname: Zhou
authors.forename: Richard C
authors.initials: RC
authors.lastname: Harvey
authors.forename: Stephen P
authors.initials: SP
authors.lastname: Hunger
authors.forename: Michael S
authors.initials: MS
authors.lastname: Kilberg
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D001215:Asparaginase / Q000494:pharmacology*; D001217:Aspartate-Ammonia Ligase / Q000037:antagonists & inhibitors / Q000096:biosynthesis* / Q000235:genetics; D045744:Cell Line, Tumor; D004305:Dose-Response Relationship, Drug; D019008:Drug Resistance, Neoplasm; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D007223:Infant; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000201:enzymology* / Q000235:genetics; D012333:RNA, Messenger / Q000096:biosynthesis* / Q000235:genetics
chemical_list: D000970:Antineoplastic Agents; D012333:RNA, Messenger; D001215:Asparaginase; D001217:Aspartate-Ammonia Ligase